Four companies went public in the past week and brought the final IPO count of 2014 up to 275 deals that raised $85 billion, making it the most active year for the IPO market since 2000. The year's record biotech boom was capped by Juno Therapeutics (+46%), the...read more
Bellicum Pharmaceuticals, an early-stage biotech developing controllable cancer immunotherapies, raised $140 million by offering 7.35 million shares (vs. 6.25 originally planned) at $19, above its $15 to $17 range. Bellicum will list on the NASDAQ under the...read more
Six deals are on the IPO calendar looking to raise a combined $1.0 billion during the week of December 15, 2014. Half of the deals are biotech IPOs, including the largest of the year...read more
Bellicum Pharmaceuticals, which is developing adjunct cancer immunotherapies based on a conditionally responsive platform, announced terms for its IPO on Tuesday. The Houston, TX-based company plans to raise $100 million by offering 6.3 million shares at a price...read more
US IPO Weekly Recap: Record 2014 IPO market finishes with a $2 billion cancer biotech
Four companies went public in the past week and brought the final IPO count of 2014 up to 275 deals that raised $85 billion, making it the most active year for the IPO market since 2000. The year's record biotech boom was capped by Juno Therapeutics (+46%), the...read more
Bellicum Pharmaceuticals prices upsized IPO at $19, above the range
Bellicum Pharmaceuticals, an early-stage biotech developing controllable cancer immunotherapies, raised $140 million by offering 7.35 million shares (vs. 6.25 originally planned) at $19, above its $15 to $17 range. Bellicum will list on the NASDAQ under the...read more
Week ahead: The 2014 IPO market's final round with 6 IPOs planned for the week of Dec 15
Six deals are on the IPO calendar looking to raise a combined $1.0 billion during the week of December 15, 2014. Half of the deals are biotech IPOs, including the largest of the year...read more
Double dose of immunotherapy: Bellicum Pharmaceuticals sets terms for $100 million IPO
Bellicum Pharmaceuticals, which is developing adjunct cancer immunotherapies based on a conditionally responsive platform, announced terms for its IPO on Tuesday. The Houston, TX-based company plans to raise $100 million by offering 6.3 million shares at a price...read more